Literature DB >> 3286513

Efficacy and safety of a single dose therapy of a 500 mg ciprofloxacin tablet in chancroid patients.

A Traisupa1, C Wongba, P Tesavibul.   

Abstract

A single dose therapy of 500 mg ciprofloxacin was sufficient to cure 15 of 18 chancroid patients within six days and the remaining three within 7, 11 and 20 days respectively. The drug was well tolerated, and no serious side effects were observed. The MICs of ciprofloxacin for the isolated Haemophilus ducreyi strains ranged from 0.0015 to 0.02 mg/l (mean 0.01 mg/l). It may therefore be concluded from our study that the oral administration of ciprofloxacin to chancroid patients with or without buboes is highly effective and free from side effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286513     DOI: 10.1007/bf01650505

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  2 in total

1.  Antimicrobial susceptibility and characterization of outer membrane proteins of Haemophilus ducreyi isolated in Thailand.

Authors:  D N Taylor; P Echeverria; S Hanchalay; C Pitarangsi; L Slootmans; P Piot
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

2.  The comparative in-vitro activity of twelve 4-quinolone antimicrobials against Haemophilus ducreyi.

Authors:  R A Wall; D C Mabey; C S Bello; D Felmingham
Journal:  J Antimicrob Chemother       Date:  1985-08       Impact factor: 5.790

  2 in total
  3 in total

Review 1.  Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 2.  Quinolone antibacterial agents for the treatment of genitourinary tract infections.

Authors:  T J Babinchak; R J Fass
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 3.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.